Rapid Affinity and IgG Titer Analytics: Automating Bioanalysis with Gyrolab Nanoliter-Scale Technology

Joy Concepcion

August 10, 2016

2 Min Read

Gyros_LOGO-300x139.jpgIn the development of biotherapeutics, there is a need to quantitate antibody titer and to characterize antibody affinity against the target of interest. Such analyses are often challenged by the need for sensitivity, reproducibility, and higher throughput. Gyrolab systems automate and miniaturize affinity measurements and IgG titer quantification in a single platform using only nanoliter volumes with rapid time to results.


Figure 1: Gyrolab huIgG titer kits provide reliable measurement of human IgG titer over a broad dynamic range and with excellent reproducibility.

IgG Titer Immunoassays with Broader Ranges for Cell Line Development
The immunoassays used to determine IgG titer must have the flexibility to support a broad range of concentrations encountered from expression to production. Gyros recently launched ready-to-use kits to rapidly measure human IgG titer at a higher throughput using only nanoliter volumes for use on Gyrolab systems. The convenience and robustness of kits combined with the automation on Gyrolab systems enable 96 data points to be generated in one hour.

Improved Reliability with Gyrolab Human IgG Titer Kits for Cell Line Development

  • Gyros1-Table1-300x66.jpg

    Table 1: Performance characteristics of Gyrolab human IgG Kit, available in two configurations

    Broader dynamic range: 1 ng/mL–1 mg/mL for clone selection and titer monitoring

  • Automation and throughput: rapid results in an hour to optimize plating density and clone selection

  • Precision and robustness: Increased reproducibility from run to run.


Figure 2: Measuring affinity (KD) using Gyrolab platforms

Rapid Affinity Measurements at Nanoliter Scale in Solution
Gyros introduced an affinity software module on its Gyrolab systems for rapid affinity characterization under in-solution equilibrium conditions. Gyrolabs’ affinity flow-through format ensures short contact times enabling KD values down to low picomolar levels and rapid measurements at higher throughput.


Table 2: Comparison of KD values of Humira®, Remicade®, and Enbrel® (Kaymakcalan Z, et al. Clin. Immunol. 131, 2009: 308–316)

Gyrolab Affinity In-Solution Kinetics for Product Characterization

  • KD values to low picomolar levels

  • Solution based measurements, uses unmodified interactants

  • Rapid measurements with throughput.

Joy Concepcion is a marketing manager at Gyros, Inc., Warren, NJ, USA; [email protected].

You May Also Like